Trevi Therapeutics
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|
Revenue | $0 | $0 | $176 |
Gross Profit | -38 | -35 | 141 |
EBITDA | -13,251 | -11,871 | -8,898 |
EBIT | -13,289 | -11,906 | -8,933 |
Net Income | -12,352 | -10,902 | -7,821 |
Net Change In Cash | 0 | 0 | 176 |
Free Cash Flow | -8,711 | -10,467 | -6,381 |
Cash | 12,963 | 13,811 | 32,397 |
Basic Shares | 101,041 | 99,517 | 99,485 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -123 | -43 | -50 | -47 |
EBITDA | -33,800 | -29,864 | -32,791 | -32,442 |
EBIT | -33,923 | -29,907 | -32,841 | -32,489 |
Net Income | -29,065 | -29,152 | -33,940 | -32,758 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | -24,241 | -12,312 | ||
Free Cash Flow | -31,847 | -28,334 | -28,946 | -29,032 |
Cash | 32,397 | 12,589 | 36,830 | 45,001 |
Basic Shares | 99,033 | 64,541 | 22,841 | 18,059 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.13 |
2024-06-30 | -$0.12 |
2024-03-31 | -$0.11 |
2023-12-31 | -$0.08 |
